Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5

Status

Completed 7Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 2NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Neoplasms 2Prostatic Neoplasms 1Glioblastoma 1Disease 1Breast Neoplasms 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × Completed × vistusertib × Clear all
NCT01597388 2026-02-24

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

AstraZeneca

Phase 1 Completed
99 enrolled 61 charts
Breast

Advanced Metastatic Breast Cancer

NCT02398747 2024-12-17

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
28 enrolled

Advanced Solid Malignancies

NCT02193633 2024-09-26

TAX-TORC

Royal Marsden NHS Foundation Trust

Phase 1 Completed
90 enrolled

Advanced Cancer

NCT02599714 2024-06-06

PASTOR

AstraZeneca

Phase 1 Completed
54 enrolled
Breast

Breast Neoplasms

NCT02619864 2023-08-04

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Canadian Cancer Trials Group

Phase 1 Completed
15 enrolled
CNS

Glioblastoma

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed
23 enrolled
Genitourinary

Disease, Neoplasms, Prostatic Neoplasms

NCT01026402 2016-02-11

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

AstraZeneca

Phase 1 Completed
172 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡